Durvalumab Approaches EU Approval for Locally Advanced PD-L1+ NSCLC

July 27, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy and whose tumors express PD-L1 on ≥1% of tumor cells. The CHMP recommendation is based on the phase III PACIFIC trial, in which the PD-L1 inhibitor improved … (leggi tutto)